Significant Ownership of Advent Life Sciences LLP

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for Advent Life Sciences LLP focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
/s/Rajesh Parekh, Ph.D. - General Partner of Advent Life Sciences LLP
Manager location
London, United Kingdom

Follow Filing Activity

Follow Advent Life Sciences LLP and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Significant Ownership of Advent Life Sciences LLP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
AURA Aura Biosciences, Inc. Common Stock, par value $0.00001 per share 3.3% $11,768,148 2,071,857 Rajesh Parekh, Ph.D. 13 Feb 2026
AFIB Acutus Medical, Inc. Common Stock, par value $0.001 per share 0% $0 0 Advent Life Sciences LLP 09 Jul 2025

Schedules 13D/G Reported by Advent Life Sciences LLP:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .